Dr. David L. Bajor, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 160
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35.128645 · PA license MD440430
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uh Cleveland Medical Center Cleveland, OH
- University Hospitals Ahuja Medical Center Beachwood, OH
- Parma Community General Hospital Parma, OH
- Uh Regional Hospitals Chardon, OH
- University Hospitals Portage Medical Center Ravenna, OH
Medical groups
- University Hospitals Medical Group Inc (2,294 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 160
- Services billed
- 533
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 251 | 121 |
| Established patient office or other outpatient visit, 40-54 minutes | 111 | 62 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 57 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 29 | 11 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | 14 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Cleveland, OH | 92 |
| Prochlorperazine Maleate Other prescribers in Cleveland, OH | 58 |
| Creon (lipase/protease/amylase) Other prescribers in Cleveland, OH | 57 |
| Potassium Chloride Other prescribers in Cleveland, OH | 47 |
| Loperamide (loperamide hcl) Other prescribers in Cleveland, OH | 45 |
| Imatinib Mesylate | 43 |
| Oxycodone Hcl Other prescribers in Cleveland, OH | 35 |
| Olanzapine Other prescribers in Cleveland, OH | 33 |
| Furosemide Other prescribers in Cleveland, OH | 32 |
| Dexamethasone Other prescribers in Cleveland, OH | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 12 payments worth $2,562 in total to this clinician.
| Corcept Therapeutics | $2,099 |
|---|---|
| Exelixis Inc. | $168 |
| Pfizer Inc. | $130 |
| Eisai Inc. | $76.35 |
| AbbVie Inc. | $56.85 |
| Janssen Biotech, Inc. | $16.09 |
| Incyte Corporation | $15.82 |
| Compensation for services other than consulting (speaking, faculty) | $1,920 |
|---|---|
| Food and Beverage | $642 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Corcept Therapeutics Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology Company’s descriptionPayment: Ad Board | $1,920 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $177,341 in research payments for these studies, mostly to the institutions running them.
- A phase 1 study of SGNEGFRD2 in advanced solid tumors
Pfizer Inc. - A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Astellas Pharma Inc - A phase 1 dose escalation and cohort expansion study of TSR-022, an an
GlaxoSmithKline, LLC. - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc. - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc. - A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma Endocrinology Inc · Terminated · NCT04799054
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.